International research indicates giving infants nirsevimab would cause sharp drop in rates of respiratory syncytial virus infection.
Respiratory syncytial virus (RSV) is a very common virus and most children will go through it without complications by the time they are two.
"We now have a way of preventing 80% of [infant] admissions due to RSV," Faust told MedPage Today. Very severe RSV-associated lower respiratory tract infection ...
A study published in the New England Journal of Medicine looks at nirsevimab for the prevention of RSV hospitalisations in infants.
The treatment could help ease seasonal pressures on the NHS, researchers said.
Abstract Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus ...
The economic burden of respiratory syncytial virus (RSV) among high-risk adults is substantial, suggesting the need to identify preventive interventions to ...
The study also found that very severe RSV associated lower respiratory tract infections occurred in five infants who received nirsevimab and 19 infants who ...
A winter vaccine for babies could cut down hospital admissions for Respiratory Syncytial Virus (RSV) by 80%, a new study has revealed.
Beyfortus (nirsevimab), a monoclonal antibody approved this summer for use in infants to protect against respiratory syncytial virus (RSV), is effective in ...
Nirsevimab efficacious for preventing RSV-associated lower respiratory tract infection and very severe RSV-associated LRTI. Nirsevimab Protects Infants ...
Flu, COVID-19 and RSV activity are increasing in Utah, and health officials expect hospitalizations and infections to keep rising through the winter.